Investors

Recent Releases

September 2, 2025

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

GAITHERSBURG, Md. , Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and

August 29, 2025

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith , and Release Recovery Founder/CEO, Zac Clark , plan to visit several U.S. college campuses to educate on opioid emergency preparedness New sponsorship of Mobilize Recovery's “Campus Surge” initiative brings

August 27, 2025

Emergent BioSolutions to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md. , Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Wells Fargo 20 th Annual Healthcare Conference September 4, 2025 3:00 pm ET